Since MYC is the identified primary target of BET inhibitors, we first looked into the activity of MYC-RhoA axis in JQ1-treated DLBCL cells to explore the major mechanism involved in BET inhibition-mediated suppression of amoeboid movement in DLBCL. This evidence concerns the gene DNER and diffuse large B-cell lymphoma.